Technical Analysis for MRUS - Merus N.V.

Grade Last Price % Change Price Change
grade B 18.61 0.00% 0.00
MRUS closed unchanged on Friday, February 14, 2020, on 86 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical MRUS trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Doji - Bearish? Reversal 0.00%
BB Squeeze Ended Range Expansion 0.00%
Outside Day Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its lead bispecific antibody candidate is MCLA-128, which is in Phase I/II clinical trials in Europe for the treatment of various solid tumors, including breast, colorectal, and ovarian cancers. The company also develops MCLA-117, a bispecific antibody candidate that is expected to commence a Phase I/II clinical trial for the treatment of patients with acute myeloid leukemia, as well as for the treatment of myelodysplastic syndrome in pre-clinical studies. Its pre-clinical bispecific antibody candidates include MCLA-134, MCLA-114, and MCLA-145, as well as other early research projects. The company has a strategic collaboration with Gustave Roussy to develop innovative bispecific antibodies for therapeutic immuno-oncology applications. Merus B.V. was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Medicine Health Immunology Antibodies Solid Tumors Monoclonal Antibodies Cancer Immunotherapy Acute Myeloid Leukemia Myelodysplastic Syndrome Monoclonal Antibody Therapy Ovarian Cancers Europe

Is MRUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 20.95
52 Week Low 11.0
Average Volume 76,931
200-Day Moving Average 15.78
50-Day Moving Average 16.40
20-Day Moving Average 17.31
10-Day Moving Average 17.66
Average True Range 0.92
ADX 17.72
+DI 18.33
-DI 14.89
Chandelier Exit (Long, 3 ATRs ) 16.25
Chandelier Exit (Short, 3 ATRs ) 17.77
Upper Bollinger Band 18.49
Lower Bollinger Band 16.13
Percent B (%b) 1.05
BandWidth 13.64
MACD Line 0.61
MACD Signal Line 0.47
MACD Histogram 0.1407
Fundamentals Value
Market Cap 360.96 Million
Num Shares 19.4 Million
EPS -5.48
Price-to-Earnings (P/E) Ratio -3.40
Price-to-Sales 36.17
Price-to-Book 3.52
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.06
Resistance 3 (R3) 20.91 19.96 20.65
Resistance 2 (R2) 19.96 19.33 20.03 20.51
Resistance 1 (R1) 19.28 18.95 18.81 19.43 20.38
Pivot Point 18.33 18.33 18.09 18.40 18.33
Support 1 (S1) 17.65 17.70 17.18 17.80 16.84
Support 2 (S2) 16.70 17.32 16.77 16.71
Support 3 (S3) 16.02 16.70 16.57
Support 4 (S4) 16.17